Resurgence in second wave of Covid-19 has led to elevated market volatility and correction. Nifty and Bank Nifty are down 5% and 15%, from the recent highs, respectively.
To contain the pandemic, several states have announced localized restrictions with Maharashtra yesterday unveiling set of broad-based measures for two weeks minilockdown. "We expect the set of restrictive measures to impact near-term economic recovery till cases stabilize. However, key government authorities and policymakers have ruled out national lockdown," said Motilal Oswal Financial Services.
Meanwhile, vaccinations are gradually beginning to accelerate. "As vaccination pick up further with approvals for more vaccines now in place, we expect the focus to shift back to growth, cyclical recovery and fundamentals," it added.
Thus, the broking firm recommends the correction as a buying opportunity and advocate adding a balanced mix of growth, cyclicals and defensive names. "We continue to be OW on the BFSI, IT, Metals, Cement & Capital Goods, Neutral on Consumer, Auto & Pharma while staying UW on Energy, Utility and Infrastructure."
India is going through a resurgent second wave of Covid-19 pandemic as the daily new confirmed cases has shot up from 10K-11K in first half of February to ~2 lakhs in April'21. Active cases have already crossed the previous peak of ~1mn and are now inching towards ~1.5million. Consequently, many states have imposed localized lockdowns and restrictions while Maharashtra has announced a 14 day lockdown with conditions to break the chain of transmission.
Case positivity rate in India is now above 11%, much higher than 1-2% at the beginning of March. The pace of spread in 2nd wave is much more intense and daily new Covid-19 cases are already 2x of the peak seen during the first wave. The cases have now spread beyond Maharashtra into other states like Chhattisgarh, Uttar Pradesh, Karnataka, Delhi etc. Maharashtra still accounts for 42% of active Covid-19 cases while Karnataka, UP, Chhattisgarh account for 6- 8% of total active cases each.
To contain the spread of cases, the government has fast tracked approval of vaccines on Emergency Use Authorization basis. It has recently approved Sputnik V vaccine. Also, it has announced that vaccines approved by drug regulators in the US, UK, European Union and Japan or those that have been cleared by the WHO will be eligible for use in India without having to conduct a local bridging trial, it added.
Pace of vaccination has started picking up in April’21 as eligibility criterion was extended to those with age >45 years. Vaccination pace has increased from 1M per day in the beginning of Mar’21 to 3.8M per day in Apr’21.
"With the approval of new vaccines, there could be further increase in the supply of doses which can boost the vaccination rate further, in our view," the broking firm said. 111 million beneficiaries have been vaccinated as of 15th April - 97.3 million have received first dose while 13.9 million have received both doses.
Rajasthan, Maharashtra, Uttar Pradesh, Gujarat and West Bengal continue to lead the vaccinations in India. They account for 45% of the total vaccines administered in India, so far, it said.
Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.
